Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

7.400 +1.110 (+17.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics Inc

< Previous 1 2 Next >
Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5
Via Investor Brand Network
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties
San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc. 
Via SBWire
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports First Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.